Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients WithEGFR-Mutated Advanced Non–Small Cell Lung Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients WithEGFR-Mutated Advanced Non–Small Cell Lung Cancer

Published:2018-08-01 Issue:8 Volume:4 Page:1080
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Aguiar Pedro N.¹,Haaland Benjamin²³,Park Wungki⁴,San Tan Pui⁵,del Giglio Auro¹,de Lima Lopes Gilberto⁴

Affiliation:

1. Centro de Estudos e Pesquisa de Hematologia e Oncologia, Faculdade de Medicina do ABC, Santo André, Brazil

2. Department of Population Health Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City

3. Department of Internal Medicine, University of Utah, Salt Lake City

4. Sylvester Comprehensive Cancer Center at the University of Miami, Miami, Florida

5. Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, England

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Reference34 articles.

1. Cancer statistics, 2016.;Siegel;CA Cancer J Clin,2016

2. EGFR testing in lung cancer is ready for prime time.;Hirsch;Lancet Oncol,2009

3. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.;Mok;N Engl J Med,2009

4. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.;Wu;Lancet Oncol,2014

5. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.;Zhou;Lancet Oncol,2011

Cited by 104 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR- mutated NSCLC: a network meta-analysis;2024-09-11

2. Cost‐effectiveness analysis of osimertinib plus chemotherapy for patients with EGFR‐mutated advanced non‐small cell lung cancer;Cancer Medicine;2024-08

3. Comparison of Classically and Machine Learning Generated Survival Prediction Models for Patients With Spinal Metastasis - A meta-Analysis of Two Recently Developed Algorithms;Global Spine Journal;2024-07-28

4. Transcriptomic Analysis Reveals Early Alterations Associated with Intrinsic Resistance to Targeted Therapy in Lung Adenocarcinoma Cell Lines;Cancers;2024-07-08

5. Real-world efficacy of adjuvant therapy for totally resected stage I lung adenocarcinoma patients with pathological high-risk factors: propensity score analysis;BMC Surgery;2024-05-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3